Novartis weighs deal for biotech Avidity to boost drug pipeline
Shares in rare disease biotech surge 26% following approach by Swiss group
Related reading
Novartis to buy Avidity Biosciences for $12bn
Deal for specialist in rare diseases is biggest acquisition under chief executive Vas Narasimhan
Eli Lilly close to buying gene-editing biotech Verve Therapeutics
Drugmaker nears $1.3bn deal in search for experimental medicines
Gilead nears up to $2bn deal for autoimmune biotech Ouro Medicines
California-based drugmaker takes advantage of surging share price to strike takeovers after a quiet couple of years
Gilead to buy cancer drug developer Arcellx for up to $7.8bn
Deal comes as pharmaceutical groups rush to acquire smaller biotech firms with proven drug pipelines
Merck nears deal for flu-prevention biotech Cidara
San Diego company’s lead drug is a potential alternative to vaccines for vulnerable patients
How AI can recode the difficult process of drug discovery
Research organisations are banking on technology to help improve the odds of approval